Immatics N.V. (IMTX)
NASDAQ: IMTX · Real-Time Price · USD
9.93
-0.37 (-3.59%)
Feb 10, 2026, 4:00 PM EST - Market closed
Immatics Employees
Immatics had 645 employees as of September 30, 2025. The number of employees increased by 73 or 12.76% compared to the same quarter last year.
Employees
645
Change
73
Growth
12.76%
Revenue / Employee
$154,178
Profits / Employee
-$218,277
Market Cap
1.33B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Sep 30, 2025 | 645 | 73 | 12.76% | 645 | 0 |
| Mar 31, 2025 | 646 | 111 | 20.75% | 646 | 0 |
| Dec 31, 2024 | 682 | 147 | 27.48% | 554 | 128 |
| Sep 30, 2024 | 572 | 139 | 32.10% | 572 | 0 |
| Jun 30, 2024 | 542 | 140 | 34.83% | 542 | 0 |
| Dec 31, 2023 | 535 | 93 | 21.04% | 432 | 103 |
| Sep 30, 2023 | 433 | 45 | 11.60% | 433 | 0 |
| Mar 31, 2023 | 402 | 29 | 7.77% | 402 | 0 |
| Dec 31, 2022 | 442 | 61 | 16.01% | 358 | 84 |
| Jun 30, 2022 | 388 | 57 | 17.22% | 388 | 0 |
| Mar 31, 2022 | 373 | 90 | 31.80% | 373 | 0 |
| Dec 31, 2021 | 381 | 98 | 34.63% | 314 | 67 |
| Sep 30, 2021 | 331 | 101 | 43.91% | 331 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,500 |
| Novavax | 952 |
| Intellia Therapeutics | 403 |
| Capricor Therapeutics | 160 |
| AnaptysBio | 136 |
| DBV Technologies | 117 |
| Taysha Gene Therapies | 73 |
| Savara | 59 |
IMTX News
- 6 weeks ago - Immatics: PRAME Leader's Transition To Commercial Reality - Seeking Alpha
- 2 months ago - Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress - GlobeNewsWire
- 2 months ago - Immatics Announces $125 Million Underwritten Offering - GlobeNewsWire
- 3 months ago - Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps - GlobeNewsWire
- 3 months ago - Immatics Appoints Amie Krause as Chief People Officer - GlobeNewsWire
- 4 months ago - Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium - GlobeNewsWire
- 4 months ago - Immatics: Multiple Clinical Catalysts In Q4'25 And 2026 - Seeking Alpha
- 6 months ago - Immatics Announces Second Quarter 2025 Financial Results and Business Update - GlobeNewsWire